Lanean...
Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Chinês |
| Argitaratua: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-08-01
|
| Saila: | Chinese Journal of Lung Cancer |
| Gaiak: | |
| Sarrera elektronikoa: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|